Insider Selling: Johnson & Johnson (NYSE:JNJ) EVP Sells 1,322 Shares of Stock

Johnson & Johnson (NYSE:JNJ) EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Timothy Schmid also recently made the following trade(s):

• On Wednesday, February 18th, Timothy Schmid sold 22,623 shares of Johnson & Johnson stock. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59.

Johnson & Johnson Trading Up 1.3%

JNJ stock traded up $3.04 during trading on Monday, hitting $245.53. The company had a trading volume of 9,620,834 shares, compared to its average volume of 9,545,482. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $246.96. The company has a 50 day simple moving average of $221.06 and a 200-day simple moving average of $199.44. The firm has a market capitalization of $591.70 billion, a P/E ratio of 22.22, a PEG ratio of 2.35 and a beta of 0.35. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion for the quarter. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bullish analyst/retail coverage highlights JNJ as a long-term buy thanks to its dividend-king status, diversification and defensive growth profile. The Only Healthcare Stock I’d Buy and Never Sell Might Be Johnson & Johnson
• Positive Sentiment: Bloomberg/InsiderMonkey report that J&J is exploring a possible sale of its orthopedics unit DePuy Synthes as part of a separation plan — a divestiture could raise cash, simplify the company and boost stakeholder returns. Bloomberg Reports Potential Major Asset Sale by Johnson & Johnson (JNJ)
• Positive Sentiment: Forbes highlights a “triple threat” — oncology sales growth, MedTech rebound, and an earnings beat — supporting upside expectations and valuation momentum. Does JNJ Stock Still Offer Value?
• Positive Sentiment: J&J is in the S&P 500 spotlight with coverage noting recent strength and investor interest, which can attract flows and lift the share price. Johnson and Johnson Surges in s&p 500 Spotlight
• Neutral Sentiment: JNJ announced a first co-funding agreement with Blackstone — a strategic partnership that could finance growth initiatives but hasn’t materially moved the stock on its own. Johnson & Johnson (JNJ) Stock Flat despite First Co-funding Agreement with Blackstone
• Neutral Sentiment: Comparative sector analysis (vs. AbbVie) and commentary on JNJ’s $32B R&D push underline longer-term growth potential but are informational rather than immediate catalysts. Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
• Neutral Sentiment: Unusual options activity was reported — suggests elevated trader interest/speculation but not a direct directional signal. Johnson & Johnson Target of Unusually High Options Trading (NYSE:JNJ)
• Negative Sentiment: German drugmaker Bayer filed a lawsuit in New York against J&J and Janssen over its Nubeqa prostate cancer drug — legal risk and potential costs introduce downside risk and headline volatility. Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
• Negative Sentiment: Commentary from Bayer frames J&J’s claims as false in ongoing disputes — continued litigation headlines could weigh on sentiment while outcomes remain uncertain. “J&J’s Claims of Superiority… Are False”: Johnson & Johnson Stock Rises despite Bayer Lawsuit

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC boosted its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the period. United Bank boosted its holdings in Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares during the period. Sivia Capital Partners LLC increased its stake in Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after purchasing an additional 692 shares during the period. Wealth Group Ltd. lifted its position in Johnson & Johnson by 12.8% in the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after purchasing an additional 168 shares during the last quarter. Finally, Matrix Asset Advisors Inc. NY boosted its stake in shares of Johnson & Johnson by 6.5% during the second quarter. Matrix Asset Advisors Inc. NY now owns 3,595 shares of the company’s stock valued at $549,000 after purchasing an additional 220 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Daiwa Securities Group boosted their price objective on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Freedom Capital cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. Bank of America boosted their price target on Johnson & Johnson from $220.00 to $221.00 and gave the stock a “neutral” rating in a research report on Thursday, January 22nd. Finally, UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $232.70.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.